Original Title: Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. Reference: Kinstner CM et al. J Am Coll Cardiol Intv. 2016;9:1386-1392. Patients with symptomatic femoropopliteal in-stent restenosis (ISR) have better patency at one year if treated with drug eluting…
BVS: Safe Also in Peripheral Territory
Original Title: Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I) 2-Year Clinical and Imaging Results CME. Reference: Johannes Lammer et al. J Am Coll Cardiol Intv. 2016;9(11):1178-1187. This is the first study on humans to assess the bioresorbable everolimus eluting vascular scaffold for the treatment of peripheral artery disease involving…
Zilver PTX: Maintains efficacy in real life most challenging lesions?
Original Title: Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan 12-Month Results. Reference: Hiroyoshi Yokoi et al. J Am Coll Cardiol Intv. 2016;9(3):271-277. This multicenter prospective study carried out in Japan assessed the paclitaxel eluting stent Zilver PTX in an unselected real world population very different to…
Drug-Coated Balloons in Complex Superficial Femoral Artery Lesions
Original Title: Drug-Coated Balloons for Complex Femoropopliteal Lesions2-Year Results of a Real-World Registry. Reference: Andrej Schmidt et al. J Am CollCardiolIntv. 2016;9(7):715-724. The superiority of drug coated balloons compared to conventional balloons in femoropopliteal lesions have been shown by randomized studies, but only in short and simple lesions. The efficacy of drug coated balloons…